ARDX Aperçu des actions
Ardelyx, Inc. est une société biopharmaceutique qui découvre, développe et commercialise des médicaments pour traiter les domaines thérapeutiques gastro-intestinaux et cardio-rénaux aux États-Unis et dans le monde entier.
| Score flocon de neige | |
|---|---|
| Évaluation | 5/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Ardelyx, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$6.09 |
| Plus haut sur 52 semaines | US$10.13 |
| Plus bas sur 52 semaines | US$3.43 |
| Bêta | 0.89 |
| 1Variation sur 1 mois | -10.70% |
| Variation sur 3 mois | 0.16% |
| Variation sur 1 an | 52.25% |
| 3Variation sur 3 ans | 403.31% |
| Variation sur 5 ans | 1.16% |
| Évolution depuis l'introduction en bourse | -56.84% |
Nouvelles et mises à jour récentes
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
Oct 24Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Recent updates
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
Oct 24Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14What To Expect For Ardelyx In The Coming Month
Oct 18Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position
Oct 04Rendement pour les actionnaires
| ARDX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 3.2% | -0.7% | -1.6% |
| 1Y | 52.3% | 19.8% | 30.8% |
Rendement vs Industrie: ARDX exceeded the US Biotechs industry which returned 19.8% over the past year.
Rendement vs marché: ARDX exceeded the US Market which returned 30.8% over the past year.
Volatilité des prix
| ARDX volatility | |
|---|---|
| ARDX Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: ARDX has not had significant price volatility in the past 3 months compared to the US market.
Volatilité au fil du temps: ARDX's weekly volatility (8%) has been stable over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2007 | 267 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc. est une société biopharmaceutique qui découvre, développe et commercialise des médicaments pour traiter les domaines thérapeutiques gastro-intestinaux et cardio-rénaux aux États-Unis et dans le monde. Le principal produit candidat de la société est le tenapanor pour le traitement des patients souffrant du syndrome du côlon irritable avec constipation. Elle développe également XPHOZAH, qui fait l'objet d'un essai clinique de phase III pour réduire le phosphore sérique chez les adultes souffrant d'insuffisance rénale chronique (IRC) sous dialyse, ou hyperphosphatémie ; RDX013, un sécrétagogue du potassium, pour le traitement du potassium sérique élevé, ou hyperkaliémie, un problème chez les patients souffrant d'insuffisance rénale et/ou cardiaque ; et RDX020, pour les patients adultes souffrant d'acidose métabolique, un trouble électrolytique grave.
Ardelyx, Inc. Résumé des fondamentaux
| ARDX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$1.44b |
| Bénéfices(TTM) | -US$72.58m |
| Recettes(TTM) | US$251.85m |
5.7x
Ratio P/S-19.9x
Ratio P/ELe site ARDX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ARDX compte de résultat (TTM) | |
|---|---|
| Recettes | US$251.85m |
| Coût des recettes | US$85.54m |
| Marge brute | US$166.31m |
| Autres dépenses | US$238.89m |
| Les revenus | -US$72.58m |
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.31 |
| Marge brute | 66.03% |
| Marge bénéficiaire nette | -28.82% |
| Ratio dettes/capitaux propres | 79.0% |
Quelles ont été les performances à long terme de ARDX?
Voir les performances historiques et les comparaisons